ABSTRACT
Petechiae (1998): Taverna C+, Schweiz Med Wochenschr (German) 128, 1117 Pruritus (1-10%) Rash (sic) (>10%) (2002): Cetkovska P+, J Eur Acad Dermatol Venereol 16(5), 481 (40-73%) Seborrheic keratoses (inflammation of) (Leser-Trélat syndrome) (1999): Williams JV+, J Am Acad Dermatol 40, 643 (1979): Kechijian P+, Ann Intern Med 91, 868 Syringosquamous metaplasia (sic) (1990): Bhawan J+, Am J Dermatopathol 12, 1 Toxic epidermal necrolysis (2001): Özkan A+, Pediatr Dermatol 18(1), 38 (1998): Figueiredo MS+, Rev Assoc Med Bras (Portuguese) 44, 53 Ulcerations (1969): Bodey GP+, Cancer Chemother Rep 53, 59 Urticaria (2002): Cetkovska P+, J Eur Acad Dermatol Venereol 16(5), 481 Vasculitis* (1998): Ahmed I+, Mayo Clin Proc 73, 239 (1989): Kerker BJ+, Semin Dermatol 8, 173 (1989): Williams SF+, Br J Haematol 73, 274
Hair Hair-alopecia (1-10%)
(1988): Benson PM+, J Assoc Military Derm XIV, 28 (passim) (1986): Morant R+, Schweiz Med Wochenschr (German) 116, 1415 (100%) (1970): Upjohn Company, Clin Pharmacol Ther 11, 155 (1969): Bodey GP+, Cancer Chemother Rep 53, 59
Nails Nails-leukonychia
(1990): Bader-Meunier B+, Ann Pediatr Paris (French) 37, 337 Nails-Mees’ lines (1982): Jeanmougin M+, Ann Dermatol Venereol (French) 109, 169
Other Anal ulceration (>10%)
Anaphylactoid reactions (1997): Blanca M+, Allergy 52, 1009 (1989): Williams SF+, Br J Haematol 73, 274 (1980): Rassiga AL+, Arch Intern Med 104, 425 Headache Hypersensitivity (1992): Weiss RB, Semin Oncol 19, 458 Injection-site cellulitis (1-10%) Myalgia (1-10%)
Oral mucosal lesions (1986): Morant R+, Schweiz Med Wochenschr (German) 116, 1415 (1-5%) (1978): Levine N+, Cancer Treat Rev 5, 67 (1974): Levantine A+, Br J Dermatol 90, 239 (66%) (1971): Lang HN+, Med J Aust 2, 187 (1968): Howard JP+, Cancer 21, 341 Oral ulceration (>10%) Pseudotumor cerebri (1999): Fort JA+, Ann Pharmacother 33, 576 Rhabdomyolysis (2002): Truica CI+, Am J Hematol 70(4), 320 Stomatitis (1988): Benson PM+, J Assoc Military Derm XIV, 28 (passim) Thrombophlebitis (>10%)
*Note: Vasculitis, a part of the cytarabine syndrome, consists of fever, malaise, myalgia, conjunctivitis, arthralgia and a diffuse erythematous maculopapular eruption that occurs from 6 to 12 hours following the administration of the drug
